Overview

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Status:
Completed
Trial end date:
2021-08-03
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Apremilast
Thalidomide